Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics for patients with neurological and psychiatric disorders. The company's lead molecule, azetukalner, is a novel potent selective Kv7 potassium channel opener currently in Phase 3 clinical trials for treating epilepsy, major depressive disorder, and bipolar depression. Xenon's pipeline also includes early-stage potassium and sodium channel modulators, with Kv7 and Nav1.7 programs in Phase 1 development for pain management. The company addresses areas of high unmet medical need in rare central nervous system conditions and other neurological disorders. Headquartered in Burnaby, British Columbia, with additional offices in Boston, Massachusetts, Xenon operates as a clinical-stage biopharmaceutical company committed to improving the lives of patients living with complex neurological conditions.